Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Int J Gynaecol Obstet. 2013 Apr;121(1):45-8. doi: 10.1016/j.ijgo.2012.11.010. Epub 2013 Jan 21.
To evaluate disease-free survival (DFS) after radical hysterectomy and pelvic lymphadenectomy (RHPL) among early-stage cervical cancer patients with single-node involvement versus patients with no nodal involvement.
A retrospective review was conducted of the medical records of 843 patients undergoing RHPL at Chiang Mai University Hospital, Thailand, between January 1, 2002, and December 31, 2008. Neoadjuvant chemotherapy was administered when the operative schedule was more than 1 month after diagnosis and adjuvant chemoradiation was administered to high-risk patients. Five subgroups were defined on the basis of pelvic node involvement: group A (0 nodes; n=706), group B (1 node; n=65), group C (2 nodes; n=38), group D (3 nodes; n=13), and group E (≥4 nodes; n=21).
The 5-year DFS was comparable for groups A and B (94.3% versus 92.1%; P=0.454). In groups C, D, and E, the 5-year DFS was 85.9%, 75.0%, and 61.8%, respectively. The survival outcomes for groups A and B were significantly different from those of the other 3 groups (P<0.001).
Cervical cancer patients with single-node involvement had comparable survival outcomes to those without nodal metastases; however, patients with multiple node involvement had reduced DFS.
评估早期宫颈癌中单一淋巴结受累患者与无淋巴结受累患者行根治性子宫切除术和盆腔淋巴结清扫术(RHPL)后的无病生存(DFS)。
对 2002 年 1 月 1 日至 2008 年 12 月 31 日在泰国清迈大学医院接受 RHPL 的 843 例患者的病历进行回顾性分析。当手术时间超过诊断后 1 个月时给予新辅助化疗,高危患者给予辅助放化疗。根据盆腔淋巴结受累情况将患者分为 5 个亚组:A 组(0 个淋巴结;n=706)、B 组(1 个淋巴结;n=65)、C 组(2 个淋巴结;n=38)、D 组(3 个淋巴结;n=13)和 E 组(≥4 个淋巴结;n=21)。
A 组和 B 组的 5 年 DFS 相当(94.3%对 92.1%;P=0.454)。C、D 和 E 组的 5 年 DFS 分别为 85.9%、75.0%和 61.8%。A 组和 B 组的生存结果与其他 3 组差异有统计学意义(P<0.001)。
单一淋巴结受累的宫颈癌患者的生存结果与无淋巴结转移的患者相当;然而,多个淋巴结受累的患者 DFS 降低。